CN1660207A - Preparation of health care for reducing blood fat and cholesterol, and producing method - Google Patents
Preparation of health care for reducing blood fat and cholesterol, and producing method Download PDFInfo
- Publication number
- CN1660207A CN1660207A CN 200410061495 CN200410061495A CN1660207A CN 1660207 A CN1660207 A CN 1660207A CN 200410061495 CN200410061495 CN 200410061495 CN 200410061495 A CN200410061495 A CN 200410061495A CN 1660207 A CN1660207 A CN 1660207A
- Authority
- CN
- China
- Prior art keywords
- mixing
- preparation
- cholesterol
- blood fat
- gets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims description 118
- 239000008280 blood Substances 0.000 title claims description 118
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 104
- 235000012000 cholesterol Nutrition 0.000 title claims description 50
- 238000002360 preparation method Methods 0.000 title claims description 44
- 230000036541 health Effects 0.000 title claims description 40
- 238000000034 method Methods 0.000 title claims description 21
- 239000003814 drug Substances 0.000 claims abstract description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 93
- 210000000582 semen Anatomy 0.000 claims description 46
- 238000002156 mixing Methods 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 238000010992 reflux Methods 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 15
- 239000013067 intermediate product Substances 0.000 claims description 15
- 238000001694 spray drying Methods 0.000 claims description 15
- 230000033228 biological regulation Effects 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 238000012856 packing Methods 0.000 claims description 10
- 235000011201 Ginkgo Nutrition 0.000 claims description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 9
- -1 and make it dry Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 abstract description 16
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 11
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 10
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000745390 Lophatherum Species 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 77
- 230000000694 effects Effects 0.000 description 74
- 238000011282 treatment Methods 0.000 description 51
- 210000004185 liver Anatomy 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 206010061876 Obstruction Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 210000000115 thoracic cavity Anatomy 0.000 description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 208000004930 Fatty Liver Diseases 0.000 description 12
- 206010019708 Hepatic steatosis Diseases 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 12
- 208000010706 fatty liver disease Diseases 0.000 description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 208000002173 dizziness Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 235000014347 soups Nutrition 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 241000218628 Ginkgo Species 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 8
- 210000003414 extremity Anatomy 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 239000004380 Cholic acid Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 229960002471 cholic acid Drugs 0.000 description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 6
- 235000019416 cholic acid Nutrition 0.000 description 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 206010008132 Cerebral thrombosis Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 230000001769 paralizing effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 206010040007 Sense of oppression Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000000055 hyoplipidemic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000237903 Hirudo Species 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 208000008630 Sialorrhea Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 229940074869 marquis Drugs 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
- 241000271039 Agkistrodon Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- NWUMSRKLBRWRAS-UHFFFAOYSA-N Arundoin Natural products COC1CCC2(C)C(CCC3C2=CCC4(C)C5CC(C)(C)CCC5(C)CCC34C)C1(C)C NWUMSRKLBRWRAS-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000237636 Pheretima Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 229960002174 ciprofibrate Drugs 0.000 description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 210000000323 shoulder joint Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 229940123324 Acyltransferase inhibitor Drugs 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 241000209514 Alismataceae Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- MRNPHCMRIQYRFU-KXUMSINMSA-N Arundoin Chemical compound C([C@]1(C)[C@@H](C(C)C)CC[C@H]1[C@]1(C)CC=C23)C[C@]1(C)[C@H]3CC[C@@H]1[C@]2(C)CC[C@H](OC)C1(C)C MRNPHCMRIQYRFU-KXUMSINMSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MRNPHCMRIQYRFU-UWAWSDATSA-N Cylindrin Chemical compound C([C@@]1(C)[C@H](C(C)C)CC[C@@H]1[C@@]1(C)CC=C23)C[C@@]1(C)[C@@H]3CC[C@@H]1[C@]2(C)CC[C@H](OC)C1(C)C MRNPHCMRIQYRFU-UWAWSDATSA-N 0.000 description 1
- BRQBMPGDACUHNR-UHFFFAOYSA-N Cylindrin Natural products COC1CCC2(C)C(CCC3C2=CCC4(C)C5CCC(C(C)C)C5CCC34C)C1(C)C BRQBMPGDACUHNR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241001251068 Formica fusca Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108010012903 IDL receptor Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002404 acyltransferase inhibitor Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 108010089310 cylindrin Proteins 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- SYKWLIJQEHRDNH-KRPIADGTSA-N glutaryl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-KRPIADGTSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000019975 isolated glycerol kinase deficiency Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for preventing and treating atherosolerosis, hypercholesterinemia, hyperlipemia, hypertension, coronary heart disease, angina pectoris, etc is prepared from haw, lophatherum, cassia seed and alismatis rhizome.
Description
Technical field
The present invention relates to a kind of health product, particularly a kind of health preparation and production method thereof with blood fat reducing and cholesterol.
Background technology
At present along with living standard raising and aged tendency of population, the cardiovascular disease incidence rate is in rising trend, the serious threat human health, about the research of coronary heart disease and atherosclerosis aspect has become clinical and focus basic research, and coronary heart disease and atherosclerosis hyperlipemia are a kind of common cardiovascular disease, mainly cause owing to metabolism disorder of blood lipid, be divided into Primary hyperlipemia and Secondary cases hyperlipemia clinically, often show as hypercholesterolemia, hypertriglyceridemia or the two have concurrently.The generation development of itself and arteriosclerosis and cardiovascular disease has closely gets in touch, and becomes the risk factor of serious threat human health.Particularly the people when hyperlipemia takes place, can bring out a series of radical reactions in the body to person in middle and old age, the damage various types of cells.Bring out the aging of vitals such as liver, brain, the health that jeopardizes middle-aged and elderly people.Therefore, seek evident in efficacy, safe and reliable hypolipidemic is the problem that medical worker studies for a long period of time always.
A lot of medical science publications and medical expert point out, suitable diet, and good living habit is the principle of transferring the fat treatment with strengthening physical training, this also is the basis of Drug therapy.The patient higher for blood fat should use lipid lowerers, the medicine that the blood lipid-lowering medicine of the present clinical practice of doctor trained in Western medicine is used for the treatment of hyperlipemia has following a few class: cholesterol biosynthesis enzyme inhibitor, i.e. HMG-CoA reductase inhibitor, cholic acid integrated agent, nicotinic acid class medicine and fibrate, cholesterol absorption inhibitor.Blood lipid-lowering medicine that other is new such as cholesterol cheese acyltransferase inhibitor and cholesterol fracture activated protein part are also in research and development.1, the cholesterol biosynthesis enzyme inhibitor mainly is meant Statins, and this compounds mainly is to suppress the synthetic rate-limiting enzyme of cholesterol-work through first glutaryl CoA reductase (HMG-COA reductase) by selectivity.This enzyme is subjected to the metabolic adjusting of body inner cholesterol, if the emptying of cell inner cholesterol causes this enzymatic activity to increase, the body inner cholesterol is synthetic to quicken and make; On the contrary, cell inner cholesterol amount increases, and this enzymatic activity descends, synthetic slowing down in the cholesterol body.Statins makes the synthetic minimizing of endogenous cholesterol in the body by suppressing the HMG-CorA reductase, reduces the source of low-density lipoprotein cholesterol.Simultaneously, such medicine increase or activate surface of hepatocytes the ML expression of receptor level and reduce the content of ML in the blood.Therefore, it is good that statins has a selectivity, the characteristics that curative effect is high, and side effect is less, can obviously reduce the atherosclerosis and evidence of coronary heart diseases and the mortality rate that are caused by hypercholesterolemia.Be the main medicine of treatment hypercholesterolemia at present.Statins has multiple at present, as lovastatin simvastatin, pravastatin, atorvastatin, newer has: as fluvastatin, long-acting fluvastatin slow releasing tablet, cerivastatin, the modal untoward reaction of such medicine mainly is slight gastrointestinal reaction, headache, cerivastatin also with liver, untoward reaction that flesh is relevant, accidental transaminase raises, the caused musclar toxicity that has comprises myalgia, myositis, rhabdomyolysis.2. fibrate, this compounds belong to the special class of shellfish, are effectively medicines of triglyceride reducing level, and that uses clinically at present mainly contains ciprofibrate, bezafibrate, fenofibrate and gemfibrozil, and the ciprofibrate side effect is big, and clinical practice is few.If such drug main is by changing the gene of coding control lipoprotein metabolism, peroxide activator enzyme hypertrophy factor activated receptor transcription factor, reduce the generation of lipoprotein by the PPAR fibrate, cause the synthetic and secretion minimizing of liver very low density lipoprotein (VLDL), increase the enzymolysis activity of lipoprotein lipase, quicken the catabolism of triglyceride.3. the nicotinic acid class is the hypolipidemic of using the earliest, and its triglyceride reducing and cholesterol levels, but the quick releasing formulation erious adverse reaction of this medicine are not used separately basically, can reduce its gastrointestinal side effect effect with food with clothes.4. cholic acid integrated agent, this class medicine comprises the hydrochloric acid colesevelam of colestyramine, colestipol and up-to-date listing.By in intestinal with the cholic acid irreversible fixation, the resorption of cholic acid in intestinal received reduced the cholic acid increase of discharging from intestinal with feces, impel hepatocyte to increase the synthetic of cholic acid, its synthesis material cholesterol consumption increases, quicken the synthetic of receptor by the feedback mechanism cell cultured supernatant simultaneously, the content of T-CHOL in the blood is reduced.This class medicine is suitable for the hypercholesterolemia of any kind except that familial hypercholesterolemia, to the Hyperglycerolemia DeGrain of any kind.The treatment of the combined hyperlipidemia that triglyceride in the serum and cholesterol are all raise, must with the hypolipidemic coupling of other types.The absorption of bile cholesterol does not influence triglyceride and fat-soluble.5. cholesteryl ester inhibitors, 3 hydroxyls of cholesteryl ester acyltransferase (AOLT) catalysis cholesterol after by long-chain acyl coenzyme A the cheese acyl group being changed over to, generate cholesterol butyric acid enzyme, and it plays an important role in the metabolism of cholesterol.The novel blood lipid-lowering medicine of a class in the ACAT inhibitor conduct research and development now, by of the absorption of inhibition body to cholesterol, thus the T-CHOL in the reduction serum.(end considers whether the people CAT homology of human and rat has similar function) under study for action, the enzymoprivic rat of normal rat and ACAT gives higher fatty acid and continuous 3 week of diet hypercholesterolemia simultaneously, and the level of the former cholesterol in serum is higher 2 times than the latter.And the former cholelithiasis occurs, and this situation appears in latter end, shows that the ACAT enzyme is a up-and-coming medicine.6. cholesterol fracture activated protein (SCAP) part, this compounds directly be positioned at the endocytoplasmic reticulum film on the sterin fracture activated protein of cholesterol regulation element conjugated protein directly combine increase IDL receptor expression.The SCAP part improves the cholesterol of animal model and the level of glycerol three cheese is better than HMG-CO people's reductase inhibitor-statins.
From as seen above-mentioned, though Western medicine has effect faster to treatment hyperlipidemia and cholesterol, a lot of side effect, particularly statins are arranged, what have becomes safety issue the most troubling and concern.
Angle from the traditional Chinese medical science, the tradition traditional Chinese medical science is thought, fatty liver is many because of eating and drinking without temperance or have a liking for food delicious food savoury and physical factors etc. and cause the liver defluidization to be let out, and dysfunction of the spleen in transportation forms that stagnation of liver-QI with deficiency of the spleen, wet knot expectorant coagulate, the card of stasis of blood resistance blood network, belongs to motherland's medical science " hypochondriac pain ", " gathering " category.Be the deficiency in origin and excess in superficiality card, sick position is dirty at liver spleen two, with the passing of time involves in kidney, shows as liver,spleen,kidney three dirty deficiencies, and its pathological factor is gas, blood, expectorant, wet, resistance.Control and to adopt the method for hepar sulfuris spleen invigorating, nourishing yin for softening liver, dispelling phlegm and eliminating dampness, phlegm reduction of blood circulation promoting at its pathogenic characteristic.Traditional Chinese medical science ancient books has many proved recipes, if any mention Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI dampness removing, the Radix Salviae Miltiorrhizae activating blood circulation to dissipate blood stasis and dredge the collateral is monarch drug altogether; Radix Curcumae, Semen Cassiae hepar sulfuris are regulated the flow of vital energy; Flos Carthami helps Radix Salviae Miltiorrhizae blood-activating and qi-promoting, disperse blood stasis and dredge collateral; Fructus Lycii, the Radix Polygoni Multiflori are strengthened the merit of invigorating spleen to remove dampness, nourishing yin for softening liver; The Folium Nelumbinis dampness removing that reduces phlegm; The Fructus Crataegi removing food stagnancy is capable to stagnate; Radix Et Rhizoma Rhei stasis removing, eliminate indigestion eliminating stagnation; The Herba Sedi clearing away heat-damp and promoting diuresis.All medicines share, and play altogether and protect the liver spleen invigorating, the effect of the dampness removing that reduces phlegm, promoting blood circulation to remove obstruction in the collateral, blood stasis-eliminating and stagnation-dissipating, and treating both the principal and secondary aspects of a disease makes spleen must be good for fortune, liver and can sulfur lets out, wetly goes expectorantization, Fructus Schisandrae Chinensis to have effects such as anti-hepatic injury, antioxidation, enhance immunity and liver detoxification function; Fructus Crataegi can quicken the removing of blood fat; Radix Et Rhizoma Rhei liver heat removing function of gallbladder promoting, stasis removing, invigorating blood circulation are strongly fragrant, and it is synthetic and suppress effect such as rising to have a lipid of interference; Radix Salviae Miltiorrhizae is a kind of blood-activating and stasis-removing, has microcirculation improvement, increases effects such as capillary network, can also remove free radical, has calcium antagonism, and it is stable to keep intracellular Ca2+, thereby brings into play the effect of its anti-hepatic necrosis.The link closely etiology and pathogenesis of fatty liver of the proved recipe that has, the coupling of many methods, treating both the principal and secondary aspects of a disease, and in conjunction with the modern medicine study achievement, according to the pathogenesis of fatty liver, select the medicine prescription pointedly, obtaining significant curative effect aspect the improvement of symptom and sign, liver function and the blood fat reducing.
It is as follows to retrieve Chinese patent related to the present invention and technical journal:
1, Chinese patent<application number〉97101570<denomination of invention〉thrombus-eliminating and brain-invigorating capsule<applicant〉Hao Yongxin<contact address〉Liaoyang City, Liaoning Province 19 innings of central hospital<claim of road ferrum of defending the country〉thrombus-eliminating and brain-invigorating capsule relates to a kind of Chinese medicine preparation for the treatment of cerebral thrombosis, trematodiasis 300 grams, Radix Ginseng 250 grams, eupolyphage sece steleophaga 800 grams, Pheretima 250 grams, Rhizoma Chuanxiong 500 grams is characterized in that fetching water, the said medicine weighing is assorted, it is qualified to concoct, be processed into 100 order powder, incapsulate.<summary〉thrombus-eliminating and brain-invigorating capsule relates to a kind of Chinese medicine preparation for the treatment of cerebral thrombosis, mainly be for the Chinese medicine that solves existing treatment cerebral thrombosis based on the plant amedica source, weak curative effect is developed treating the worse problem of numb effect.The present invention mainly with Hirudo, Radix Ginseng, eupolyphage sece steleophaga, Pheretima, Rhizoma Chuanxiong and Scolopendra, Radix Et Rhizoma Rhei, Zaocys etc., to also have Semen Cassiae, Formica fusca etc. be raw material, formulated, the treatment cerebral thrombosis is controlled numbness, lipid-lowering effect is very good.
2, Chinese patent<application number〉95121615<denomination of invention〉a kind of Chinese medicine preparation<applicant of reducing fat and dilating coronary artery〉Zhang Baosen, He Lanfeng<contact address〉No. 62<summary in Qing Yuan street, Shijiazhuang City, Hebei Province city〉a kind of Chinese medicine preparation of reducing fat and dilating coronary artery, it is characterized in that following finished product Chinese medicine (weight is gram) fully: Radix Astragali 300-400 Herb Gynostemmae Pentaphylli 300-400 Herba Epimedii 100-200 Fructus Ligustri Lucidi 100-200, mix after boil and carry, precipitate with ethanol, concentrate, obtain extracting solution.In extracting solution, add zinc gluconate, sodium selenite etc. and add ingredients, through leave standstill, packing and sterilization, promptly obtain this preparation.This preparation has effects such as blood fat reducing, strong kidney and strengthening spleen.
3, Chinese patent<application number〉00133594<denomination of invention〉hypolipemic ' Tongluowan '<applicant〉Wang Zhigang<contact address〉Da Tun township, Qingfeng County, Henan Province assembles East St clinic<summary greatly〉a kind of medicine that cures mainly cardiovascular and cerebrovascular vessel, it is by Rhizoma Gastrodiae, Agkistrodon, Semen Persicae, Rhizoma Chuanxiong, Hirudo, Fructus Crataegi, the Radix Astragali, Ramulus Cinnamomi, Radix Salviae Miltiorrhizae is main medicine, it is the medicine of blood fat reducing collateral dredging, wherein adopt Agkistrodon, Rhizoma Gastrodiae, the Hirudo activating blood circulation to dissipate blood stasis, the medicine principle of Fructus Crataegi blood fat reducing cooperates realization, cost of the present invention is low, the curative effect height, more do not recur after, curing effective percentage can reach more than 87%.
4, Chinese patent<application number〉03153559<denomination of invention〉health promoting beverage<applicant〉Gao Si<contact address〉No. 62 3 unit of East Village, mud hilllock, Luohu District, Shenzhen City, Guangdong Province 106 Room<summaries〉the invention discloses one group of several health promoting beverage, be primarily aimed at hyperlipidemia, high blood viscosity, atherosclerosis, coronary heart disease, easy hemopoietic bolt high-risk group and fat personage the diet-therapy health-preserving opsonic action is arranged, suitably take into account the needs of diabetics and prophylaxis of cancer, health promoting beverage is taken good care of in custom-designed daily dietetic therapy.It is made by following twenty kind of natural medicine-food homology raw material choice: Ganoderma, Flos Lonicerae, Fructus Crataegi, Folium Nelumbinis, the Radix Astragali, Folium Camelliae sinensis, Folium Stevlae Rebaudianae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Polygonati, Rhizoma Alismatis, Herb Gynostemmae Pentaphylli, Fructus Ligustri Lucidi, Radix Salviae Miltiorrhizae, Radix Ginseng, Radix Notoginseng, Fructus Lycii, Fructus Corni, Rhizoma Chuanxiong, Radix Rehmanniae Preparata, Radix Angelicae Sinensis, its common feature is: adopt natural material, be processed into one group of plesiomorphic beverage of taste, suitability for industrialized production is transported, stores, is drunk conveniently.Often drink, conditioning lipid metabolism, blood fat reducing are all arranged, fall sticking, the pre-preventing thrombosis of blood and coronary heart attack and atherosclerosis, reach gradually and suppress body weight gain and reduce fat effect, normal drink has no side effect.
5, Chinese patent<application number〉03114248<denomination of invention〉a kind of blood fat reducing and slow down aging pharmaceutical composition and medicine<applicant〉Shenzhen Haiwang Pharmaceutical Co., Ltd<contact address〉25 layers of Building A, Haiwang Building, Nanyou Avenue, Nanshan District, Shenzhen City, Guangdong Province<summary〉compositions and the preparation thereof of Chinese medicine drug extract of a kind of effectively blood fat reducing and slow down aging, said composition is the dried leaves extract that contains Semen Ginkgo, the dry root and rhizome extract of Radix Rhodiolae, the medicament of the dry mature fruit extract of Fructus Schisandrae Chinensis, by weight, described Folium Ginkgo extract, Radix Rhodiolae extract, the extract combination ratio of Fructus Schisandrae Chinensis is: Folium Ginkgo extract: Radix Rhodiolae extract=1: 0.5~2: 0.75~3, have defying age and blood fat reducing function, taking convenience, tool health-care effect and the characteristics that have no side effect.
6, Chinese patent<application number〉02146744<denomination of invention〉the Chinese medicine electuary<applicant of blood fat reducing〉Wang Wei<contact address〉king top, Nankai District, Tianjin City dike Rong Qian Dongli 14-5-503 number,<summary〉a kind of Chinese medicine electuary of blood fat reducing, form by following component ratio: by weight, Rhizoma Cyperi 1-3 part, Fructus Aurantii 2-4 part, Fructus Gardeniae 4-6 part, Radix Bupleuri 2-4 part, Rhizoma Chuanxiong 5-6 part, Fructus Schisandrae Chinensis 4-7 part, Semen Cassiae 2-5 part, Fructus Crataegi 5-8 part, Cortex Mori 3-6 part, Folium Perillae 2-4 part, Ramulus Cinnamomi 5-7 part; More than every medicine be crushed into powder and be mixed in proportion.Effect of the present invention is: through clinical confirmation in large quantities, it can be when reducing blood viscosity vessel softening, around improving and the circulation of cardiovascular and cerebrovascular vessel, improve the body constitution function, reduce glyceride, promote the lipase function, thus the blood fat reducing viscosity.
7, fat soup treatment fatty liver 90 examples [author] Zhang Jianwei of intending certainly dispelling turns round and look at the Shaanxi traditional Chinese medical science .2002 of brave main [mechanism] Zhongshan Hospital Attached to Fudan Univ [periodical name], 23 (1) .[digests] purpose: the curative effect of observing the treatment by Chinese herbs fatty liver.Method: adopt from intending fat soup (Fructus Crataegi, Radix Salviae Miltiorrhizae, Rhizoma Alismatis, Semen Cassiae, Rhizoma Polygoni Cuspidati, Folium Nelumbinis etc.) treatment fatty liver 90 examples of dispelling, result: total effective rate 91.11%.Through Ridit and t check, change relatively before and after fatty liver, the hyperlipidemia treatment, the P value is respectively<and 0.05,<0.01.Short term effect is satisfied.Point out this method to have lowering fat and protecting liver, improve liver, activate the drawback that lipoprotein enzyme Western medicine decreases liver and have for the effect of penetrating.
8, capsule for descend of blood fat is treated [mechanism] Jingjiang City, Jiangsu Province institutes of traditional Chinese medicine such as the virtuous Liu Can health of hyperlipemia 180 routine observation of curative effect [author] He Jing, [periodical name] Jilin Chinese medicine .2002,22 (1) .[digests] purpose: observe the curative effect of capsule for descend of blood fat to hyperlipemia.Method: treatment is organized 180 examples and is given capsule for descend of blood fat, and matched group 90 examples give oral inositol cigarette ester sheet.Observe treatment front and back TC, TG, HDL-C changes of contents.Result: TC, TG, HDL-C changes of contents compare P all<0.05 before and after 2 groups of treatments, compare P<0.05 after treatment group and the treatment of control group; Treatment group total effective rate is 93.33%, and the matched group total effective rate is 68.89%, P<0.05.Conclusion: by reducing the absorption and the increase of lipid are drained the decomposition of lipid by the capsule for descend of blood fat that Fructus Crataegi, Semen Cassiae, Radix Polygoni Multiflori, Rhizoma Alismatis, Radix et Rhizoma Rhei (processed), Radix Angelicae Sinensis, Fructus Lycii etc. are formed, play altogether and let out turbid blood stasis dispelling, the effect of tonifying speen and tonifying kidney, reach the purpose of adjusting blood fat, every curative effect index all obviously is better than matched group.
9, the Henan College Of Traditional Chinese Medicine journal .2003 of blood fat reducing soup treatment hyperlipemia 52 routine clinical research [author] Sun Yongli [mechanism] the Shanghai City Zhabei District hospitals of traditional Chinese hospital [periodical name], 18 (4) .[digests] blood fat reducing soup is made up of medicines such as Semen Cassiae, Fructus Crataegi (parched to brown), Flos Chrysanthemi, Flos Carthami, Radix Polygoni Multiflori, Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, Rhizoma Alismatis.Clinical treatment group 52 examples are taken blood fat reducing soup, produce effects 34 examples, effective 14 examples, invalid 4 examples, effective percentage 92.30%; Matched group 38 examples are taken many rare Weikang capsule for curing, produce effects 15 examples, effective 12 examples, invalid 11 examples, effective percentage 71.05%.
10, transfer the safe Chen Yu brightness Zhou Ying [mechanism] of the strong liver soup treatment of fat fatty liver 60 routine clinical observation [author] the Yang Fu hospital of traditional Chinese hospital, Tianhe District, Guangzhou City, Guangdong Province, [periodical name] new traditional Chinese medical science .2004,36 (3) .-39-40[digests] purpose: observe the curative effect of transferring the strong liver soup treatment of fat fatty liver.Method: 105 routine patients are divided into treatment group and matched group at random.60 examples are organized in treatment, and the strong liver soup of fat (prescription: Fructus Crataegi, Radix Polygoni Multiflori, Radix Salviae Miltiorrhizae, Poria, Pericarpium Citri Reticulatae, Rhizoma Alismatis, Endothelium Corneum Gigeriae Galli, stir-fry Rhizoma Curcumae, Rhizoma Pinelliae Preparatum, Semen Cassiae, Rhizoma Curcumae Longae, Radix Notoginseng end) of transferring for oral administration is treated; Matched group 45 examples, oral Herb Gynostemmae Pentaphylli total glycosides tablet, inosine sheet.The result: treatment group produce effects 20 examples, effective 37 examples, invalid 3 examples, total effective rate is 95.0%: matched group produce effects 7 examples, effective 25 examples, invalid 13 examples, total effective rate is 71.1%.2 groups of total effective rates compare, and difference has highly significant meaning (P<0.01).Conclusion: transfer the strong liver soup of fat can promote the metabolism of liver inner lipid effectively, lipid reducing and regulating has the good curing effect to fatty liver.
From above-mentioned data searching, still have morely with the data of Chinese herbal treatment hyperlipemia, they respectively have characteristics, and its major function is vessel softening when reducing blood viscosity, around improving and the circulation of cardiovascular and cerebrovascular vessel.
Summary of the invention
The inventor is on the basis of secret prescription handed down in the family from generation to generation, at people in the modern life usually because diet do not note and work, live and social pressure, cause hyperlipidemia and cholesterol easily, cause the generation utilization Chinese medical theory of arteriosclerosis and cardiovascular disease more preferred Chinese medicines, make the health preparation of a kind of blood fat reducing and cholesterol, to health care fill a prescription in addition the science compatibility, make that each medicine cooperatively interacts, learns from other's strong points to offset one's weaknesses, synergism, make it to produce maximum effect, given play to due usefulness.
The health preparation that the present invention has blood fat reducing and cholesterol is to be made by the raw material of Chinese medicine of following mass fraction:
Fructus Crataegi 10-20
Herba Lophatheri 10-20
Semen Cassiae 12.5-25
Rhizoma Alismatis 17.5-35
The health preparation raw material of blood fat reducing of the present invention and cholesterol is through the modern science analysis, has needed by human body number of chemical composition, as: triterpenoid, arundoin, Cylindrin, match alcohol, left-handed epicatechin, Quercetin, hyperin, chlorogenic acid, citrate, emodin, obtusin, betanin, volatile oil, alkaloid, asparagine and polytype polysaccharide, multivitamin, various trace elements, inorganic elements, nicotinic acid, multiple soap is sweet, citric acid sheep formicester, flavan polymers, ursolic acid, glucosan, alkanoic acid glyceride etc.
The health preparation raw material of above-mentioned blood fat reducing and cholesterol can be from " finding its another name, latin name and the place of production, usage Chinese pharmacopoeia and other Chinese medicine handbook, for understanding the mechanism of the present invention's prevention and inhibition disease, now provide the effect and the pharmacological thereof of the Chinese medicine of respectively distinguishing the flavor of in the prescription:
(1) Fructus Crataegi: sour in the mouth, sweet, slightly warm in nature.Digestion-promoting spleen-invigorating, promoting blood circulation to remove blood stasis, diuresis, enhancing immunity, antibiotic, antioxidation, anti-cancer.Fructus Crataegi comes from China, is the exclusive seeds of China, and the fruit vitamin C is higher, more contains multiple nutrients composition (flavone, protein, potassium, calcium, ferrum, zinc, manganese, magnesium, phosphorus etc.), has more than 80 kind of Chinese patent medicine to be unable to do without simultaneously and does raw material with Fructus Crataegi.Particularly contain blood fat reducing and cholesterol effect, be subjected to the great attention of domestic and international medical circle, show through animal experiment, Fructus Crataegi can be improved the hormone-sensitive lipase activity significantly, quickens lipid mobilization and promotes the gastrointestinal wriggling.The fat-reducing test shows, can suppress the increase of nutrition obese type rat body weight significantly, reduces the volume of adipose cell, alleviates body fat quality and blood fat reducing level, has fat-reducing effect preferably.
(2) Herba Lophatheri, Herba Lophatheri are the dry stem and leaf of grass Herba Lophatheri, and the beginning is stated from Compendium of Material Medica, and " Chinese pharmacopoeia is all recorded to go through version.The dried root of Herba Lophatheri is elongated spindle, microbend, long 1-4cm, and diameter 0.2-0.5cm, surperficial yellow-white have irregular wrinkle to khaki, meat slightly, section is talked yellow-white, and it is little sweet to distinguish the flavor of.Herba Lophatheri sweet in the mouth, light, cold in nature, GUIXIN, stomach, small intestine meridian, tool clearing heat and relieving fidgetness, diuretic effect.Be used for the calentura excessive thirst, hot urination drenches pain, and aphtha of the mouth and tongue etc. belong to conventional Chinese medicine.Stem, leaf contain trisulfide, acid ingredient, aminoacid, organic acid and saccharide etc., also are one of the most frequently used medical herbs among the people, have both made medicine, make the health care herbal tea of relieving summer heat again, and it all has fabulous DEVELOPMENT PROSPECT at aspects such as medicinal, health-care tea beverages.Herba Lophatheri is used as medicine later, and Ming Dynasty's Compendium of Material Medica beginning is seen record.Li Shizhen (1518-1593 A.D.) claims it: sweet, cold, nontoxic.Leaf: go dysphoria with smothery sensation, diuresis clears away heart-fire.Root: the name Rhizoma lophantheri, can have an abortion to expedite the emergence of.Record among the people, Herba Lophatheri are clearing away heart-fires simply, heat clearing away and restlessness relieving, and the good medicine of diuresis, thirsty to the treatment calentura, vexed uneasiness, the erosion of the oral mucosa tongue boil, tooth swells and ache age, and hot urination drenches pain, and effect is quite arranged.The contained functional component of Herba Lophatheri mainly is: trace element such as flavone, phenolic acid compound, aminoacid, ferrum, manganese, zinc.Related data shows: these effective ingredient can be removed activity in vivo oxygen-derived free radicals (it can impel people's aging); Blocking nitrosamine formation is synthetic; Induce the activity of the antioxidase system of organism inside; The anti-stress of enhancing body and anti-fatigue ability; Improve memory ability, the process of slow down aging etc.Can also protect medicament as cardiovascular and cerebrovascular vessel, antitumor drug etc.Also can use simultaneously at aspects such as health product, functional drinkss.
(3) Semen Cassiae is Semen Cassiae again, is the dry mature seed of leguminous plant Semen Cassiae or little Semen Cassiae, and nature and flavor are sweet, bitter, salty, be slightly cold, and returns liver, large intestine channel, and the effect of liver heat removing and eyesight improving, diuretic relieving constipation is arranged.Modern study shows, pharmacological action such as Semen Cassiae protects the liver, makes eye bright, blood pressure lowering, blood fat reducing.Naturally drink of the influence of the Semen Cassiae water decoction of variable concentrations under the physiological status to the alimentary obesity rat body weight, found that the Semen Cassiae water decoction of 6% concentration can obviously suppress the increase of alimentary obesity rat body weight, and do not influence appetite, there is not the diarrhoea effect that causes, has health-care effect preferably, bibliographical information is arranged, observe under the rat physiological status and drink of the influence of Semen Cassiae water decoction naturally, and tentatively inquire into its mechanism of action the alimentary obesity body weight.Method: make the obese rat model with high nutrient fodder, allow rat under physiological status, drink the Semen Cassiae water decoction of variable concentrations naturally, observe its influence to rat body weight and sugar, lipid metabolism and lipoid peroxidization resistant.The result: the Semen Cassiae water decoction of 6% concentration can obviously reduce body weight, Lee ' s index, empty stomach serum triglycerides, insulin and the mda content of alimentary obesity rat, free fatty acid content also has downward trend, and the Total antioxidant capacity level has rising trend.Conclusion: the Semen Cassiae water decoction can obviously suppress the increase of alimentary obesity rat body weight, and its mechanism of action may be relevant with its adjusting glucose and lipid metabolism.
(4) Rhizoma Alismatis, Rhizoma Alismatis are the dry tuber of Alismataceae plant Rhizoma Alismatis Alisma orientalis (Sam.) Juzep..Cold in nature, sweet in the mouth, light is returned kidney, urinary bladder channel.The effect that have promoting diuresis to eliminate damp pathogen, expels the heat-evil.Be used for dysuria, edema distension, have loose bowels, disease such as oliguria, phlegm retention, dizzy, puckery pain of pyretic stranguria.The application of Rhizoma Alismatis in recent years is very extensive, pharmacological action, and 1. Rhizoma Alismatis has tangible diuresis, and to contain a large amount of potassium salt relevant with it for this.2. blood fat reducing and study of anti-atherogenic effect, Rhizoma Alismatis can obviously reduce serum total cholesterol, triglyceride, promote serum, level raises, obviously suppress the generation of aortic tunica intima speckle, in addition, Rhizoma Alismatis extract also has antiplatelet aggregation, antithrombotic to form and strengthens effect such as plasmin activity, thus can be from blood fat reducing, suppress many-side inhibition such as endothelial cell damage, antithrombotic or alleviate atherosclerotic generation, development.3. lipotropy, Rhizoma Alismatis all has good effect through the component of methanol, benzene and acetone extraction to the Animal fat liver that a variety of causes causes, fatty liver due to low protein diet, the ethionine all there is in various degree inhibitory action, 4. hypotensive activity, Rhizoma Alismatis and extract thereof have hypotensive effect to a certain degree.5. to immune influence and antiinflammatory action, the Rhizoma Alismatis decoct is given the mouse peritoneal injection with 10g/Kg, 20g/Kg, continuous 5 days, discovery can suppress the mice carbon powder and clean up speed and 2, contact dermatitis due to the 4-dinitrochlorobenzene, and content of ascorbic acid in serum antibody level and the rat adrenal gland is not made significant difference; The Rhizoma Alismatis decoct then can obviously alleviate the mice auricle swelling that dimethylbenzene causes with the 20g/kg intraperitoneal administration, suppresses rat granuloma hamartoplasia, and the prompting Rhizoma Alismatis has antiinflammatory action.
The mechanism of action of blood fat reducing of the present invention and cholesterol health preparation is:
Except operating pressure and factor of environmental, the urbanization of the higher fatty acid and modern inhabitation of food at present, make person in middle and old age's disease incidence in rising trend, for example serious threat human health, cardiovascular and cerebrovascular disease has risen to three human big diseases, relevant hyperlipidemia, hyperglycemia, hypercholesterolemia and cause coronary heart disease and the research of atheromatosis aspect has become clinical and focus basic research, therefore, preventing cardiovascular disease and restrain tumor, is an outstanding feature of the present invention.The inventor studies Traditional Chinese medical theory, on the basis of secret prescription handed down in the family from generation to generation, replenished and put in order, excavate and develop and a kind of plurality kinds of health care Chinese medicine is share, the deficiency of vital energy can be mended, blood stasis can loose, and wind-phlegm can be dispelled, suppressing the hyperactive liver and subsiding YANG, play benefiting QI for activating blood circulation altogether, eliminating phlegm relieves dizziness, high fever, infantile convulsions, epilepsy, etc., disperse blood stasis and dredge collateral, treating both the principal and secondary aspects of a disease it, it can improve myocardial function, blood vessel dilating, blood fat reducing, blood sugar lowering, cholesterol reducing alleviates atherosclerosis, strengthen human body cell metabolism number of times prolonged human body life time, slow down aging and the imbalance of adjusting viscera function suppress body building health preparation of tumor and preparation method thereof.The characteristic that the present invention has is as follows:
(1) slightly warm in nature, digestion-promoting spleen-invigorating, promoting blood circulation to remove blood stasis, diuresis, enhancing immunity.Each organ function equilibrium of conditioning human body viscera improves body immunity, effective two-ways regulation human immunity state, and the resist the disease factor, and harmful pathogenic bacteria is invaded human body.
(2) induce the activity of the antioxidase system of organism inside; The anti-stress of enhancing body and anti-fatigue ability; Improve memory ability, the process of slow down aging can be used as cardiovascular and cerebrovascular vessel protection medicament, and antitumor drug etc. are induced the activity of the antioxidase system of organism inside; The anti-stress of enhancing body and anti-fatigue ability; Improve memory ability, the process of slow down aging etc.Can also protect medicament as cardiovascular and cerebrovascular vessel, antitumor drug etc.
(3) protect the liver, make eye bright, blood pressure lowering, blood fat reducing, promote the human body metabolism to make human nerve, endocrine operational network normal.Improve myocardial function, blood vessel dilating brings high blood pressure down, and promotes hemopoietic function, blood fat reducing, and blood sugar lowering, cholesterol reducing alleviates atherosclerosis, and blood circulation promoting and blood stasis dispelling impels blood leukocytes and hemoglobin to increase, and wound healing is fast.
So, blood fat reducing of the present invention and cholesterol health preparation have been followed whole existing the thought and the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs principle of motherland's medical science, the rule of development takes place in research and inquirement hypertension theoretically, hyperlipidemia, and adopt blood circulation promoting and blood stasis dispelling, hard masses softening and resolving, heat-clearing and toxic substances removing, the body resistance strengthening and constitution consolidating etc. to have " operation " means of Chinese medicine characteristic, accomplish " medication is as using military forces ", ability " To know one's own strength and the enemy's is the sure way to victory "
Above-mentioned composition can be used as middle age prevention hyperlipidemia, hypercholesterolemia, supression fatty liver and causes coronary heart disease and the health preparation of atheromatosis, also can be used as hospital's prescription, provides patient to fry in shallow oil soup and takes.Be more suitable for modern pharmaceutical enterprise and extract its effective ingredient, make any dosage form of health product such as capsule, granule, oral liquid, concrete production method is as follows:
1, the production method of capsule:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, encapsulated dress gets the finished capsule product agent.
2, granule production method;
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, drying, packing gets the finished particle agent.
3, oral liquid production method;
(1) get whole Fructus Crataegis, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis mixing pulverizing, with the alcohol reflux twice of volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets the alcohol extraction part A;
(2) medicinal residues after the above-mentioned alcohol extraction and Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis are added 5-8 times of water gaging decoction twice, each 2-3 hour, get water and carry part B:
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, add an amount of syrup or Mel mixing, sterilization gets the finished product oral liquid.
4, the manufacture method of teabag
The manufacture method of teabag is to get Chinese medicine mix homogeneously such as Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, pulverizes 80 mesh sieves, adds 5 times of tea packagings; Perhaps add Folium Ginkgo, pulverize, packing is made teabag.
5, the production method of pill:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and Mel and adjuvant (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, also filtering residue can be added, stir, make pill, and make it dry, coating promptly obtains product.
6, tablet manufacturing method:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, tabletting, packing gets finished tablet.
The instructions of taking of the health preparation of the present invention's blood fat reducing of the present invention and cholesterol:
Capsule, every day three times, each 3, every 0.5 gram; Granule, every day three times, each 1 bag, every bag 7 gram; Oral liquid, every day three times, each 10ml; Tablet, every day three times, each 2-3 sheet, every 0.3 gram.Patient doubles, and the child quantitatively takes according to body weight and adult's ratio.Other preparation is taken as the case may be.
The present invention compared with the prior art, its outstanding substantive distinguishing features and obvious improvement is:
1, the present invention's more preferred raw material of Chinese medicine with blood fat reducing and cholesterol health preparation commonly used under Chinese medical theory instructs, science compatibility, making in addition, make that each raw material cooperatively interacts, learns from other's strong points to offset one's weaknesses, synergism, all medicines share, the deficiency of vital energy can be mended, and blood stasis can loose, and wind-phlegm can be dispelled, suppressing the hyperactive liver and subsiding YANG is played benefiting QI for activating blood circulation, the effect of the eliminating phlegm that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., disperse blood stasis and dredge collateral, treating both the principal and secondary aspects of a disease altogether.
2, through clinical verification, the present invention can suppress, eliminate atherosclerosis, suppresses hypercholesterolemia and hyperlipidemia, the promoting blood circulation thrombus dissolving, the infractionization that disappears high blood viscosity, anti-platelet aggregation is unusual, antihypertensive can improve the cerebrovascular metabolic function, the resisting cerebrovascular sclerosis, it is capable to improve blood, and activating brain cell and brain function can be used for premonitory apoplexy, apoplexy sequela, the thoracic obstruction, also can be used for coronary heart disease, angina pectoris, high blood viscosity, hyperlipemia etc., treat the disease spectrum width, with strong points, evident in efficacy.
3, from the angle analysis of modern medicine, the present invention has the pathological changes that alleviates ischemic rat brain, reduces the permeability of cerebral tissue blood capillary and the water content of cerebral tissue, anticoagulant and thrombosis, cerebral blood flow increasing amount and oxygen-supplying amount, functions such as blood lipid reducing, blood sugar concentration.
4, raw material is easy to get, the prescription science, and production technology advanced person, workable, moderate product price is fit to suitability for industrialized production.
5, produce in according to the effective ingredient character and the preparation requirement of each flavor raw material of Chinese medicine, adopt or alcohol extraction, or water carries, or the production technology of pulverizing and corresponding sterilizing methods, thereby product active constituent content height, and not perishable long shelf-life.
6, the result of product studies on acute toxicity of the present invention and long term toxicity research shows, is safe by intending using product of the present invention the course of treatment with daily dose.
The specific embodiment
Below be embodiments of the invention:
Embodiment one
(1) take by weighing Fructus Crataegi 20 gram, Herba Lophatheri 20 grams, Semen Cassiae 25 grams, Rhizoma Alismatis 35 grams mix and pulverize, and cross 80 mesh sieves, add 2500 milliliters of clear water and boil 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, encapsulated dress gets hundred million yuan of blood fat reducing capsules of product.
Embodiment two:
(1) get Fructus Crataegi 18 gram, Herba Lophatheri 16 grams, Semen Cassiae 22 grams, Rhizoma Alismatis 25 grams mix and pulverize, and cross 80 mesh sieves, add 3000 milliliters of clear water and boil 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, add 2 times of syrup, wiring solution-forming, sterilization gets hundred million yuan of oral administration liquor for reducing blood fat of finished product.
Embodiment three:
(1) get Fructus Crataegi 20 gram, Herba Lophatheri 20 grams, Semen Cassiae 25 grams, Rhizoma Alismatis 35 grams, mix and pulverize, cross 80 mesh sieves, add 2000 milliliters in clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, drying, packing gets hundred million yuan of blood fat reducing granules of finished product.
Embodiment four:
(1) get whole Fructus Crataegis 20 grams, Herba Lophatheri 20 grams, Semen Cassiae 25 grams, Rhizoma Alismatis 35 grams, mix and pulverize, with the alcohol reflux twice of volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets the alcohol extraction part A;
(2) medicinal residues after the above-mentioned alcohol extraction and Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis are added 5-8 times of water gaging decoction twice, each 2-3 hour, get water and carry part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get dried cream powder C, with appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, sugar coating gets hundred million yuan of blood fat reducing coated tablets of finished product.
Embodiment five:
Get Fructus Crataegi 16 grams, Herba Lophatheri 16 grams, Semen Cassiae 20 grams, Rhizoma Alismatis 28 grams, four kinds of Chinese medicine mix homogeneously were pulverized 80 mesh sieves, added 5 times of tea packagings; Perhaps add Folium Ginkgo, pulverize, packing is made teabag.
Embodiment six:
(1) get Fructus Crataegi 15 gram, Herba Lophatheri 15 grams, Semen Cassiae 19 grams, Rhizoma Alismatis 33 grams, mix and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, tabletting, packing gets finished tablet.
Embodiment seven:
(1) get Fructus Crataegi 10 gram, Herba Lophatheri 10 grams, Semen Cassiae 12.5 grams, Rhizoma Alismatis 17.5 grams, mix and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, encapsulated, get hundred million yuan of blood fat reducing capsules of finished product.
Embodiment eight:
(1) get Fructus Crataegi 18 gram, Herba Lophatheri 18 grams, Semen Cassiae 18 grams, Rhizoma Alismatis 18 grams, mix and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, encapsulated, get hundred million yuan of blood fat reducing capsules of finished product.
Embodiment nine:
(1) get Fructus Crataegi 18 gram, Herba Lophatheri 13 grams, Semen Cassiae 21.5 grams, Rhizoma Alismatis 30.5 grams, mix and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get dried cream powder C, add an amount of syrup or Mel mixing, make pill, sterilization gets hundred million yuan of blood fat reducing balls of finished product.
Below be clinical research report of the present invention:
Blood fat reducing of the present invention and cholesterol health preparation entrust certain city-level hospital to carry out clinical verification:
Clinical data:
One, physical data,
Job step and experimental result are as follows:
Coronary disease with angina pectoris 70 examples all are higher than normal value through blood check blood fat.Wherein 40 examples are organized in treatment, male's 25 examples, and women's 15 examples, age 48--70 one full year of life,, 62.16 ± 7.33 years old mean age (X ± SD).Matched group 30 examples, male's 20 examples, women's 10 examples, age 45---70 year, average 59.31 ± 7.96 years old.Two groups of sexes, age distribution all do not have significant difference (P>0.05).
Be and have thoracic obstruction main symptom; Chinese medical discrimination belongs to syndrome of blood stasis due to qi deficiency, and Western medicine diagnose meets the angina pectoris standard, and patient more than 2 times shows effect weekly.Wherein 40 examples are organized in treatment, male's 25 examples, and women's 15 examples, the age is in 40---70 year, average 63.39 ± 6.73 years old (X ± SO).Matched group 30 examples, male's 16 examples, women's 14 examples, age 40-70 year, average 58.734-8.84 year (X ± SD).Two groups of sexes, age distribution all do not have significant difference (P>0.05).
Two, diagnostic criteria
1, coronary heart disease:
(1) primary symptom: the apoplexy phenomenon is arranged, the hemiplegia that has, numbness.
(2) Acute onset.
(3) crooked mouth and tongue, mind unconsciousness, stiff tongue and retardation in speech or in silence, hemianesthesia.
(3) sick sending out has inducement more, and premonitory symptom is often arranged before not sending out.
(4) how send out the age well more than 40 years old.
The selection coronary disease with angina pectoris is the object of observation.
Deficiency of vital energy blood match pattern of syndrome standard is, hemianesthesia, and pale complexion, shortness of breath and fatigue, mouthful sialorrhea is perspired, dimly pale tongue, thin white fur of tongue or white greasy, deep-thready pulse, slow or thin string carefully.
Wind-phlegm blood stasis, numbness resistance venation pattern of syndrome standard is: hemianesthesia, have a dizzy spell dimly pale tongue, thin white fur of tongue or white greasy.
2. the thoracic obstruction:
(1) chest is gloomy, very then chest pain radiating to the back.
(2) the lighter only becomes chest distress, hypopnea.
(3) Electrocardioscopy has the ischemic change or the exercise test positive.
Select in the thoracic obstruction deficiency of vital energy blood to examine the card patient and be the object of observation.Its pattern of syndrome standard is: feeling of oppression and pain in the chest, breathe hard, cardiopalmus, dizzy, dark tongue quality or ecchymosis is arranged, deep and stringy pulse or heavy thin.
Observational technique
Observe 70 examples altogether, be divided into 2 groups at random.Thoracic obstruction patient treatment group 40 examples, matched group 20 examples.The treatment group each 2, every day 3 times, serve on for 4 weeks with medicine of the present invention " hundred million yuan of blood fat reducing capsules ".Matched group is with Ginkgo oral liquid (productions of the XX of Hebei province city pharmaceutical factory), and each 10ml serve on for 4 weeks every day 3 times, and routine is made detailed physical examination to the patient before the test, with relevant physico-chemical examination, as electrocardiogram, blood fat, hemorheology, waist wear, CT scan etc.Change of illness state is kept a close eye in the test back, makes pathography weekly 1 time, as finding that the state of an illness obviously worsens, should stop test immediately and take other integrative therapy measures, and therapeutic effect is evaluated with scoring method.The curative effect judgement is directly made by the observer.Viewing duration is withdrawn the Chinese and western drugs that influences the coronary heart disease curative effect in principle.Heavier to the state of an illness, withdraw the other drug person of having any problem, can be with the Western medicine application limitations at citicoline (paralytic) and nitroglycerin (thoracic obstruction patient), other Chinese medicines and Chinese patent medicine are withdrawn without exception.Finish the relevant physico-chemical examination of back check the course of treatment.
Three, therapeutic outcome:
1. to the influence of various symptoms, sign: observe behind two kinds of treatment for diseases groups and the matched group patient treatment the various witness integrations equal highly significant that descends, illustrate that two kinds of medicines all have therapeutical effect to the apoplexy and the thoracic obstruction, treatment back paralytic's mind, language are blind, the motor function and the thoracic obstruction are patient's feeling of oppression and pain in the chest, and symptoms such as shortness of breath and palpitation, sign all have clear improvement.
2, two kinds of medicines compare onset time thoracic obstruction patient: treatment group paralytic is that (X ± SD), obviously faster than matched group (30.5 ± 1.29 week), two groups of differences have significance (P<0,05) to 2.SS+0.99 onset time.Treatment group thoracic obstruction person is that 2.61 ± 1.13 weeks, (X ± SD) was slower than matched group (2.48 ± 1.21, two groups of difference and significance (P>0.05) slightly onset time.
Before and after the thoracic obstruction patient physico-chemical examination treatment relatively, two groups of patient treatment after-contraction pressures, diastolic pressure, ch and TG all have obvious decline (P<0,05), and HDL increases nonsignificance (P>0,05), treatment group hemorheology improves obviously (P<0,01).
4. treatment group and matched group curative effect are relatively, 70 examples are organized in paralytic's treatment, total effective rate is 89%, matched group 30 examples, and total effective rate is 76.7%, treatment group curative effect obviously is better than matched group (P<0,01), thoracic obstruction patient treatment group 30 examples, its heart strand carbuncle curative effect, ECG curative effect, clinical card marquis curative effect total effective rate are respectively 90,0%, 60.0%, 83,4%.Matched group 30 examples, very main angor curative effect, Jb electrograph curative effect, clinical card marquis curative effect total effective rate is respectively 93.3%, 63.3%, 93,3%, two groups of relatively more equal nonsignificances (P>0,05) of curative effect.
Two groups of patients all do not find obvious adverse reaction and toxic and side effects at viewing duration.
Model case
Example 1, Liu XX, man, 62 years old.
Because have sudden faint companion speech unfavorable, the left limb moving obstacle is admitted to hospital in emergency treatment on February 6 in 2004 half a day.Conscious having a dizzy spell, palpitation and night sweat, hemianesthesia.Inspection is seen: refreshing clear, crooked mouth and tongue sialorrhea, and language performance is owed entirely, lifts on the left shoulder joint and can not put down shoulder, and articulations digitorum manus only can be clenched fist, and left side leftover bits and pieces hip joint still can stretch in the wrong but a little less than the power, toe joint is stretched Qu Buquan, dark tongue quality, white and greasy fur, deep-thready pulse.Diagnose through CT examination: right side temporal lobe cerebral infarction, tcm diagnosis: apoplexy (apoplex involving the channels and collaterals-wind-phlegm blood stasis type).With hundred million yuan of blood fat reducing capsule for treating of the present invention, every day three times, each 6.Take medicine only two weeks, hemiplegia, having a dizzy spell begins to alleviate, and shoulder joint has gone up lifts flat shoulder, and life can partial self-help.After 30 days, former symptom disappears substantially, and patient's life can be taken care of oneself, continues to take hundred million yuan of blood fat reducing capsules, and June 9, recovery from illness was left hospital.
Example 2, Wei XX, woman, 48 years old.
The patient is admitted to hospital on November 3rd, 2003 because of " pain uncomfortable in chest, hypopnea 1 hour ", conscious pain uncomfortable in chest, shortness of breath and fatigue, cardiopalmus, has a dizzy spell.Inspection sees that lustreless complexion, asthenia lazyness are blind, dark tongue quality has speckle, white and thin fur, deep-thready pulse.Electrocardioscopy is shown: T1V3-6 is low flat, tcm diagnosis; Thoracic obstruction Qi deficiency blood stasis type, Western medicine diagnose: angina pectoris.With hundred million yuan of blood fat reducing capsule for treating of the present invention, day obeying each 63 times.After, sensation of oppression over the chest with shortness of breath, the weak beginning of cardiopalmus alleviate, and are kept to 1 time for 2 times the every day of feeling of oppression and pain in the chest when being admitted to hospital, time, pain degree obviously alleviated by being kept to 10 minutes half an hour, around the after, pain uncomfortable in chest is not reaccessed, only surplus slightly breathing hard and dizzy symptom, and surplus disease disappears.Check electrocardiogram: normal ECG roughly.Curative effect to treat angina pectoris, ECG curative effect and clinical card marquis efficacy evaluation are produce effects.
Conclusion:
Above clinical data discloses:
1. blood fat reducing of the present invention and cholesterol health preparation have the promote blood circulation effect of brain-strengthening suppressing the hyperactive liver of inrigorating qi and promoting blood circulation, dispelling pathogenic wind and eliminating phlegm, blood stasis dispelling, and cerebral infarction card, angina pectoris due to blood stasis due to qi deficiency, wind-phlegm blood stasis, the passages through which vital energy circulates impatency are had therapeutical effect.
2, blood fat reducing of the present invention and cholesterol health preparation have blood pressure lowering, effect for reducing blood fat, and hemorheology is also improved significantly, and prompting offsets except that symptom before the apoplexy, and reducing cerebrovascular disease has certain preventive and therapeutic effect.
3. blood fat reducing of the present invention and cholesterol health preparation treatment paralytic 70 examples, total effective rate is 89%, curative effect is better than the Ginkgo oral liquid that XX city, Hebei province pharmaceutical factory produces.The treatment thoracic obstruction 30 examples, the total effective rate of angina pectoris, electrocardiogram, symptom curative effect is for being respectively 90.0%, 60.0%, 83,4%, curative effect and ginkgo oral liquid no significant difference.
4. this product is safe and reliable, and 130 examples are not all found obvious adverse reaction and toxic and side effects at viewing duration
The embodiment of blood fat reducing of the present invention and cholesterol health preparation treatment hyperlipidemia and hypercholesterolemia:
Tang * *, the woman, nineteen sixty-eight gives birth to, Nanning people from city is because of suffering from hyperlipidemia, concurrent hypertension, coronary heart disease, often dizzy, asthma upstairs, at the beginning of 2003 in certain hospitalize, take the Western medicine lovastatin, but symptom makes moderate progress, but the symptom commentaries on classics of not getting better after the drug withdrawal, after change and take " hundred million yuan of blood fat reducing capsules ", every 0.5 gram, every day 3 times, each 6, and take hundred million primordial oral liquids, 2 of every days, 10 milliliters every, take that frequent dizzy symptom takes a turn for the better after 20 days, take one month after, symptom all disappears, spirit takes a turn for the better, muscle power increases, and is of pink and healthy-looking, feels good.
The land * *, man, life in 1949, haunt and plague left people from city in Guangxi, on June 10th, 2003 was suffered from coronary heart disease at examination in hospital, often angina pectoris, dyspnea owing to lack of capital and be not in hospital, is taken " hundred million yuan of blood fat reducing sheets " every day 3-4 time, totally 30, every 0.3 gram, and take hundred million primordial oral liquids, 2 of every days, 10 milliliters every, take two all aftersensation and get that sb.'s illness took a favorable turn, breathe smooth and easyly, present anginal symptom takes a turn for the better.
Yellow * *, woman, life in 1956, Baise of Guangxi people from city, numb limbs and tense tendons, distortion of commissure, sialorrhea, slurred speech, crank uneasiness.Take " hundred million yuan of blood fat reducing capsules " in October, 2003 after 20 days, numb limbs and tense tendons alleviates, artistomia, take 5 months after, walking is convenient, thing can do housework.
Open * *, the man, nineteen fifty gives birth to, Baise of Guangxi people from city.Autumn in 2003, the household catch sight of open * * go home very late, the vestige of falling and falling is arranged on the clothes trousers, but the household is when asking that he is why, he says nothing, just says and does not know, can not remember, and is very unclear in a minute.Sending inspection to hospital through the household just knows because cerebral arteriosclerosis causes cerebral thrombosis, brain atrophy, brain dementia.Take " hundred million yuan of blood fat reducing capsules " in November, 2003 after one month, it is more steady to walk, and keeps one's legs, and it is strong that extremity are felt, it is clearer to speak, some recovery of memory, and after half a year, disease disappears substantially to take " hundred million yuan of blood fat reducing capsules ".
The king * *, the man, nineteen fifty-two gives birth to, the worker that retires due to illness of Nanning city unit.Because of suffering from brain bolt disease for many years, numb limbs and tense tendons be can't take care of oneself, inarticulateness, and temper is dry, pessimism.Begin to take " hundred million yuan of blood fat reducing capsules " every day three times in March, 2004, each five, behind the first quarter moon, extremity begin that consciousness is arranged, and it is conscious strong to hold object, and mood is also felt better, take 6 months continuously after, can walk, live and can take care of oneself, articulate, speak with fluency.
High * *, the man, nineteen fifty-five gives birth to, the laid-off worker of Liuzhou city unit catches sight of myasthenia of limbs in August, 2003, a species of orchid circle when walking, the difficulty of drinking water, on inspection, there is infraction in the brain stem district, because of financial difficulties can not be in hospital for a long time, in December, 2003 is taken " hundred million yuan of blood fat reducing capsules " every day three times, and each 4, behind the first quarter moon, the sensation extremity are strong, and it is more stable to walk, and it is smooth and easy to drink water, mood is also happy, take half a year after, disease symptoms is eliminated.
Claims (8)
1, the health preparation of a kind of blood fat reducing and cholesterol is characterized in that: said preparation is to be made by the raw material of Chinese medicine of following mass fraction:
Fructus Crataegi 10-20; Herba Lophatheri 10-20; Semen Cassiae 12.5-25; Rhizoma Alismatis 17.5-35.
2, the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that: said preparation is any dosage form on the pharmaceutics.
3, the preparation method of the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that producing by the following method capsule:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials mixing, granulate, encapsulated dress gets the finished capsule product agent.
4, the preparation method of the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that producing by the following method tablet:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, tabletting, packing gets finished tablet.
5, the preparation method of the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that producing by the following method granule:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
(2) with the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and appropriate amount of auxiliary materials (by the adjuvant of state-promulgated pharmacopoeia regulation) mixing, granulate, drying, packing gets the finished particle agent.
6, the preparation method of the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that producing by the following method teabag:
Get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis kind Chinese medicine mix homogeneously, pulverized 80 mesh sieves, add 5 times of tea packagings; Perhaps add Folium Ginkgo, pulverize, packing is made teabag.
7, the preparation method of the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that producing by the following method pill:
(1) get Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis, mixing and pulverize, cross 80 mesh sieves, add clear water and boiled 10-30 minute, filter, boil again, totally twice, preserve filtrate A;
With the alcohol reflux twice of filtering residue with volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets alcohol extraction part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, spray drying gets intermediate products dried cream powder C;
(4) get C and Mel and auxiliary materials and mixing, stir, make pill, and make it dry, coating promptly obtains product.
8, the preparation method of the health preparation of a kind of blood fat reducing as claimed in claim 1 and cholesterol is characterized in that producing by the following method oral liquid:
(1) get whole Fructus Crataegis, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis mixing pulverizing, with the alcohol reflux twice of volume by volume concentration 55-70%, each 2-3 hour, extracting solution reclaimed ethanol and gets the alcohol extraction part A;
(2) medicinal residues after the above-mentioned alcohol extraction and Fructus Crataegi, Herba Lophatheri, Semen Cassiae, Rhizoma Alismatis are added 5-8 times of water gaging decoction twice, each 2-3 hour, get water and carry part B;
(3) A and B mixing are concentrated, get relative density 1.05-1.20/55-60 ℃ fluid extract, add an amount of syrup or Mel mixing, sterilization gets the finished product oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410061495 CN1660207A (en) | 2004-12-29 | 2004-12-29 | Preparation of health care for reducing blood fat and cholesterol, and producing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410061495 CN1660207A (en) | 2004-12-29 | 2004-12-29 | Preparation of health care for reducing blood fat and cholesterol, and producing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1660207A true CN1660207A (en) | 2005-08-31 |
Family
ID=35009945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410061495 Pending CN1660207A (en) | 2004-12-29 | 2004-12-29 | Preparation of health care for reducing blood fat and cholesterol, and producing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1660207A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926899A (en) * | 2010-09-07 | 2010-12-29 | 许阳 | Health-care medicament for hyperlipemia and preparation method thereof |
| CN102488198A (en) * | 2011-11-18 | 2012-06-13 | 天津天狮生物发展有限公司 | Antioxidant health food preparation for protecting cardiovascular system and its preparation method |
| CN102550810A (en) * | 2012-03-06 | 2012-07-11 | 杨正 | Environment-friendly tea feed containing black tea, dark tea, bamboo leaf and hawthorn |
| CN103599408A (en) * | 2013-10-31 | 2014-02-26 | 广西健丰药业有限公司 | Traditional Chinese medicine oral liquid and preparation method thereof |
| CN104489716A (en) * | 2014-12-29 | 2015-04-08 | 唐华 | Health preparation capable of preventing and treating cardiovascular diseases of human body and production method of health preparation |
| CN106266320A (en) * | 2015-06-11 | 2017-01-04 | 葛以东 | A kind of formula controlling high blood viscosity |
-
2004
- 2004-12-29 CN CN 200410061495 patent/CN1660207A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926899A (en) * | 2010-09-07 | 2010-12-29 | 许阳 | Health-care medicament for hyperlipemia and preparation method thereof |
| CN101926899B (en) * | 2010-09-07 | 2011-10-26 | 许阳 | Health-care medicament for hyperlipemia and preparation method thereof |
| CN102488198A (en) * | 2011-11-18 | 2012-06-13 | 天津天狮生物发展有限公司 | Antioxidant health food preparation for protecting cardiovascular system and its preparation method |
| CN102550810A (en) * | 2012-03-06 | 2012-07-11 | 杨正 | Environment-friendly tea feed containing black tea, dark tea, bamboo leaf and hawthorn |
| CN103599408A (en) * | 2013-10-31 | 2014-02-26 | 广西健丰药业有限公司 | Traditional Chinese medicine oral liquid and preparation method thereof |
| CN103599408B (en) * | 2013-10-31 | 2016-03-02 | 广西健丰药业有限公司 | A kind of Chinese medicine oral liquid and preparation method thereof |
| CN104489716A (en) * | 2014-12-29 | 2015-04-08 | 唐华 | Health preparation capable of preventing and treating cardiovascular diseases of human body and production method of health preparation |
| CN106266320A (en) * | 2015-06-11 | 2017-01-04 | 葛以东 | A kind of formula controlling high blood viscosity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101467582B (en) | Refined lift-lengthening tea | |
| CN101011561B (en) | Huanglian Wendan Decoction modern traditional Chinese medicine oral preparation and production method thereof | |
| CN104825816A (en) | Medicine for treating fatty liver, prostatitis, diabetes, nephralgia and kidney deficiency | |
| CN103169793B (en) | Medicine for treating hypertension, hyperlipoidemia and diabetes mellitus | |
| CN101715851A (en) | Weight reducing tea and manufacturing process thereof | |
| CN104758806A (en) | Decocted extract for treating coronary heart disease and preparation method thereof | |
| CN103749824B (en) | A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN1660387A (en) | Health care preparation for regulating functional balance of organs of bowels in human body and preparing method | |
| CN101104038A (en) | Decoction medicine for treating liver qi stagnancy biliary ascariasis and preparation method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN103463407A (en) | Body regulating and blood sugar reducing capsule | |
| CN103520302A (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| CN1060028C (en) | Health food macte from cereal, vegetable and fruit | |
| CN107927781B (en) | Traditional Chinese medicine weight-losing meal replacement | |
| CN105079532A (en) | Healthcare green tea capable of reducing blood fat and loosing weight and preparation method of healthcare green tea | |
| CN105641383A (en) | Traditional Chinese medicine lozenge with fat-reducing effect and preparation method thereof | |
| CN104605372A (en) | Nutritional herbal cuisine based on cancer radiotherapy patient and preparation method thereof | |
| CN102552743A (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN102205010A (en) | Pharmaceutical composition with auxiliary function of reducing blood fat | |
| CN101884760B (en) | Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN101884758B (en) | Food therapy preparation for preventing and treating cerebrovascular diseases based on theories of preventive treatment of disease and medicine food homology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wei Pingsheng Document name: Deemed as a notice of withdrawal (Trial) |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |